Plasmablasts as Translational Biomarkers in Autoimmune Diseases: From Cellular Dynamics to Clinical Decision-Making
Current Issues in Molecular Biology · 12.01.2026 · 48 (1) · 77
DOI: 10.3390/cimb48010077 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 12.01.2026. Verfasst von Muhammad Soyfoo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
B cells are key drivers of immune dysregulation across systemic autoimmune diseases. Among their progeny, plasmablasts occupy a uniquely revealing niche: short-lived, highly proliferative intermediates that mirror real-time B-cell activation. Their appearance in peripheral blood integrates antigenic stimulation, cytokine-driven differentiation, and aberrant germinal-center dynamics, transforming them into sensitive indicators of ongoing immunological activity. This review synthesizes current knowledge on plasmablast biology and highlights disease-specific phenotypes across systemic lupus erythematosus (SLE), primary Sjögren disease (pSjD), IgG4-related disease (IgG4-RD), ANCA-associated vasculitis (AAV), and rheumatoid arthritis (RA). We incorporate molecular insights from single-cell technologies that have uncovered previously unrecognized plasmablast subsets, metabolic states, and interferon-related signatures with prognostic and mechanistic value. Beyond descriptive immunology, plasmablasts are emerging as dynamic biomarkers capable of informing real-time clinical decisions. One of the most robustly supported applications is the prognostic interpretation of plasmablast kinetics following B-cell-depleting therapies, where early reconstitution patterns consistently predict relapse across multiple autoimmune conditions. As clinical immunology shifts from static serological markers toward kinetic, cell-based monitoring, plasmablast quantification offers a path toward precision immune surveillance. Integrating plasmablast dynamics into routine care may ultimately allow clinicians to anticipate disease flares, time therapeutic reinforcements, and transition from reactive management to preventive intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Hôpital Erasme, Université Libre de Bruxelles (ULB), 1070 Brussels, Belgium.
ORCID-Profile: Muhammad Soyfoo, Julie Sarrand
Zitieren
APA
Soyfoo, M., & Sarrand, J. (2026). Plasmablasts as Translational Biomarkers in Autoimmune Diseases: From Cellular Dynamics to Clinical Decision-Making. Current Issues in Molecular Biology, 48(1), 77. https://doi.org/10.3390/cimb48010077
Vancouver
Soyfoo M, Sarrand J. Plasmablasts as Translational Biomarkers in Autoimmune Diseases: From Cellular Dynamics to Clinical Decision-Making. Current Issues in Molecular Biology. 2026;48(1):77. doi:10.3390/cimb48010077
BibTeX
@article{Soyfoo2026,
author = {Soyfoo, Muhammad and Sarrand, Julie},
title = {Plasmablasts as Translational Biomarkers in Autoimmune Diseases: From Cellular Dynamics to Clinical Decision-Making},
journal = {Current Issues in Molecular Biology},
year = {2026},
volume = {48},
number = {1},
pages = {77},
doi = {10.3390/cimb48010077}
}
EUVIMED